Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Sathana Dushyanthen, Zhi Ling Teo, Franco Caramia, Peter Savas, Christopher P Mintoff, Balaji Virassamy, Melissa A Henderson, Stephen J Luen, Mariam Mansour, Michael H Kershaw, Joseph A Trapani, Paul J Neeson, Roberto Salgado, Grant A McArthur, Justin M Balko, Paul A Beavis, Phillip K Darcy, Sherene Loi
Nature Communications | NATURE PUBLISHING GROUP | Published : 2017
Related Projects (3)
Awarded by NHMRC
We thank Ralph Rossi, Vicki Milovac, and Sophie CurcioPeter from MacCallum Cancer Centre (PMCC) FACS facility. Kaushalya Amarasinghe; PMCC Animal facility and technicians, PMCC Cytotoxic suite, PMCC Bioinformatics core. Laura Kilpatrick and Amy Rogers (Cancer Cell Death Laboratory) for providing the OT-I cells. This work was funded by project grants from the National Breast Cancer Foundation (NBCF), Australia and the National Health and Medical Research Council (NHMRC). S.L. is supported by Cancer Council, Victoria, Australia and the Breast Cancer Foundation (BCRF), N.Y. P.A.B. is supported by Fellowships (ID# PF-14-008). P.K.D. and M.H.K. are supported by NHMRC Senior Research Fellowships (APP1041828 and APP1058388), respectively.